• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Feb 7, 2023
    Insmed To Present at the SVB Securities Global Biopharma Conference
  • Feb 3, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jan 20, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jan 6, 2023
    Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
  • Jan 3, 2023
    Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
  • Dec 6, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 30, 2022
    Insmed To Present at the Nasdaq 47th Investor Conference
  • Nov 4, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 1, 2022
    Insmed To Present at Three November Conferences
  • Oct 27, 2022
    Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List
  • Oct 27, 2022
    Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update
  • Oct 19, 2022
    Insmed Announces Strategic Financings Totaling $775 Million
  • Oct 13, 2022
    Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022
  • Oct 7, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Oct 6, 2022
    Insmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service
  • Sep 7, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 6, 2022
    Insmed To Present at Two September Conferences
  • Aug 5, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 4, 2022
    Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update
  • Jul 21, 2022
    Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022
  • Jul 8, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jun 3, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 23, 2022
    Insmed Names Drayton Wise Chief Commercial Officer
  • May 17, 2022
    Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference
  • May 17, 2022
    Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference
  • May 6, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 5, 2022
    Insmed Reports First Quarter 2022 Financial Results and Provides Business Update
  • Apr 21, 2022
    Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
  • Apr 7, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Mar 28, 2022
    Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference
  • Mar 4, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Mar 3, 2022
    Insmed To Present at the Cowen 42nd Annual Health Care Conference
  • Feb 17, 2022
    Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least 30% Year Over Year Annual Growth for 2022--
  • Feb 10, 2022
    Insmed To Present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference
  • Feb 4, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jan 27, 2022
    Insmed to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide a Business and Pipeline Update on Thursday, February 17, 2022
  • Jan 4, 2022
    Insmed To Present at the 40th Annual J.P. Morgan Healthcare Conference
  • Dec 6, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 5, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 3, 2021
    Insmed To Participate in Three November Conferences
  • Oct 28, 2021
    Insmed Ranks No. 1 on Science's 2021 Top Biopharma Employers List
  • Oct 28, 2021
    Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan--
  • Oct 14, 2021
    Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021
  • Oct 5, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 3, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 1, 2021
    Insmed To Participate in Five September Conferences
  • Aug 6, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 5, 2021
    Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories--
  • Jul 27, 2021
    Insmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021
  • Jul 8, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Show 5102550100 per page
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy